Association of the Sialylation of Antibodies Specific to the HCV E2 Envelope Glycoprotein with Hepatic Fibrosis Progression and Antiviral Therapy Efficacy

Table 1

The characteristics of patients under investigation .

HCV genotype ()	Hepatic fibrosis stage				Response to treatment
	0	1	2	3	4	SVR	NR	RL	ST
	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
1b (51)	26 (51)	9 (17,6)	5 (9,8)	3 (5,9)	8 (15,7)	24 (47,1)	10 (19,6)	14 (27,5)	3 (5,9)
3a (46)	21 (45,7)	14 (30,4)	6 (13)	1 (2,2)	4 (8,7)	37 (80,4)	1 (2,2)	5 (10,9)	3 (6,5)
1a+2a/2c (6)	4 (66,7)	1 (16,7)	1 (16,7)	0 (0)	0 (0)	5 (83,3)	0 (0)	0 (0)	1 (16,7)
All cases (103)	51 (49,5)	24 (23,3)	12 (11,7)	4 (3,9)	12 (11,6)	66 (64,1)	11 (10,7)	19 (18,5)	7 (6,8)

Genotype 1a: one patient; GT 2a/2c: 5 patients. SVR: sustained virologic response; NR: no response, RL – relapse. In seven patients treatment was stopped (ST) due to intolerance.